Following last year’s acquisition of viral vector and plasmid specialist Forge Biologics, Japan’s Ajinomoto Bio-Pharma Services is streamlining its business in San Diego.
Fierce Pharma
Internet News
New York, New York 93,059 followers
Pharma’s go-to destination for news & trends shaping approved drugs.
About us
Fierce Pharma is the go-to destination for the news and trends shaping the industry. Our focus daily is on news about approved drugs and every aspect of pharma’s operations as well as the people who move pharma forward. Our coverage also feeds longer-form content, podcasts and events. In staying on top of the news, our journalists have developed a loyal audience. Critically, we explain the news—often complicated technology or business maneuvers—and put it in context that brings it home for our readers and listeners in their work lives. Delivering news, revealing insights straight to your inboxes: https://fiercepharma.questexinfo.com/loading.do?omedasite=Pharma_full. Our family of publications includes Fierce Pharma, Fierce Pharma PM Tracker, Fierce Pharma Marketing, Fierce Manufacturing, Fierce Drug Delivery and Fierce Life Sciences Weekly Digest. Follow our podcast ‘The Top Line’ on Apple Podcasts, Spotify, Amazon, iHeart or wherever you get your podcasts. We dig into high-impact trends and recount the week’s biggest headlines. For Biotech news you can’t miss: https://www.linkedin.com/showcase/fierce-biotech For Healthcare news you can’t miss: https://www.linkedin.com/showcase/fierce-healthcare
- Industry
- Internet News
- Company size
- 51-200 employees
- Headquarters
- New York, New York
- Type
- Privately Held
- Founded
- 2006
Locations
-
Primary
685 3rd Ave
21st Floor
New York, New York 10017, US
Employees at Fierce Pharma
Updates
-
Despite being a topic of a U.S. intelligence briefing, Legend Biotech is "not too concerned that we’re the target of the BIOSECURE bill," the CAR-T company's CEO Ying Huang said.
Legend Biotech CEO takes ‘close look at business’ amid geopolitical risk, M&A rumor
fiercepharma.com
-
While Apellis Pharmaceuticals has spent much of the year working around setbacks that derailed the ongoing launch of its geographic atrophy drug Syfovre, a major phase 3 triumph could open up a new market for the drugmaker.
Apellis, Sobi's 'enormous' Empaveli win could pressure Novartis in rare kidney diseases: analyst
fiercepharma.com
-
A year after it was hit with a rejection from the FDA, Citius Pharmaceuticals has scored an approval for Lymphir to treat cutaneous T-cell lymphoma.
Citius notches first FDA approval, scoring with Lymphir for cutaneous T-cell lymphoma
fiercepharma.com
-
As multiple drugmakers race to bring novel, levodopa-based Parkinson’s disease treatments to the market, New Jersey’s Amneal Pharmaceuticals has taken home the gold in the U.S.
After 2023 snub, Amneal clinches approval for extended-release Parkinson's disease med Crexont
fiercepharma.com
-
Register today for Curis’s 3rd Annual Symposium on IRAK4 in Cancer, featuring expert presentations on the promise of IRAK4 inhibition and clinical outcomes of the IRAK4 inhibitor emavusertib. Register here: https://cvent.me/kDaoDK #Sponsored #IRAK4 #Emavusertib #AML #Lymphoma #Cancer
-
Novo Nordisk’s attempt to gain an approval to treat heart failure patients with its obesity drug Wegovy has been put on hold.
Novo Nordisk pulls its FDA heart failure submission for Wegovy, will reapply early next year
fiercepharma.com
-
Amid Bayer's massive reorganization, the company's pharma group is moving full steam ahead toward market expansions for key products.
Bayer looks ahead to Nubeqa, Kerendia expansions amid Xarelto's downward sales spiral
fiercepharma.com
-
While Pfizer’s German mRNA partner BioNTech has high hopes for its post-COVID future, the company continues to feel the squeeze from the changeover to a seasonal vaccine market.
BioNTech posts €808M loss as company continues to come to grips with seasonal COVID vaccine market
fiercepharma.com
-
Months of an ongoing supply squeeze for Eli Lilly and Company's tirzepatide-based meds have lifted, according to the FDA.
Eli Lilly's Mounjaro, Zepbound back in stock after extended shortage, FDA says
fiercepharma.com